納米魯單抗
化合物
納米魯單抗（INN：namilumab；開發代號：MT203），或譯那美蘆單抗，是一種人單株抗體（IgG1 κ類），靶向粒細胞-巨噬細胞集落刺激因子（簡稱GM-CSF或CSF2），目前正在研究用於類風濕性關節炎和銀屑病關節炎。[1][2][3]納米魯單抗正在進行I期和II期臨床試驗，以確定該抗體在斑塊型銀屑病[4]和類風濕性關節炎中的安全性、耐受性和初步治療效用。[5][6]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | CSF2 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 1206681-39-1  |
| ChemSpider |
|
| UNII | |
參考資料
- ^ World Health Organization. International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 104 (PDF). WHO Drug Information. 2010, 24 (4).
- ^ Huizinga T, Batalov A, Stoilov R, Lloyd E, Wagner T, Saurigny D, Souberbielle B, Esfandiari E. Namilumab, an Anti-Granulocyte Macrophage-Colony Stimulating Factor (GM-CSF) Monoclonal Antibody: Results of the First Study in Patients with Mild-to-Moderate Rheumatoid Arthritis (RA): Abstract Number: 969. Arthritis & Rheumatology. October 2015, 67.
- ^ 3.0 3.1 Namilumab. Adis Insight. Springer Nature Switzerland AG. [2017-03-24].
- ^ Clinical trial number NCT02129777 for "Efficacy and Safety of Namilumab (MT203) for Plaque Psoriasis" at ClinicalTrials.gov
- ^ A 24-week Randomized, Open-Label, Parallel-Group, Active-Controlled, Exploratory, Proof-of-Mechanism Imaging Study Investigating the Efficacy of 150 mg of Namilumab Administered Subcutaneously vs Adalimumab in Patients With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate. Adis Insight. Springer Nature Switzerland AG. [2017-03-24].
- ^ Clinical trial number NCT02379091 for "Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA)" at ClinicalTrials.gov
- ^ Namilumab. Takeda clinical trials summary.